Virus Dataset Sample Info

> Dataset: 28107423 Search Result


Summary
Item Summary
Project 28107423
Virus Name HIV
Sample Number 7
Disease injection drug user(IDU) infection
Country China
Data Link https://www.ncbi.nlm.nih.gov/sra/SRS1830977
https://www.ncbi.nlm.nih.gov/sra/SRS1830978
https://www.ncbi.nlm.nih.gov/sra/SRS1830979
https://www.ncbi.nlm.nih.gov/sra/SRS1830980
https://www.ncbi.nlm.nih.gov/sra/SRS1830981
https://www.ncbi.nlm.nih.gov/sra/SRS1830982
https://www.ncbi.nlm.nih.gov/sra/SRS1830983

Sample
ID Sample ID Age Gender Origin Detail
1 TW_D38 37 M China View
2 TW_D53 38 M China View
3 TW_D83 28 M China View
4 TW_D78 51 M China View
5 TW_D848 31 M China View
6 TW_D854 37 M China View
7 TW_D855 41 M China View

Literature
Item Summary
PMID 28107423
Title Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.
Abstract The usefulness of ultra-deep pyrosequencing (UDPS) for the diagnosis of HIV-1 drug resistance (DR) remains to be determined. Previously, we reported an explosive outbreak of HIV-1 circulating recombinant form (CRF) 07_BC among injection drug users (IDUs) in Taiwan in 2004. The goal of this study was to characterize the DR of CRF07_BC strains using different assays including UDPS. Seven CRF07_BC isolates including 4 from early epidemic (collected in 2004-2005) and 3 from late epidemic (collected in 2008) were obtained from treatment-naive patient's peripheral blood mononuclear cells. Viral RNA was extracted directly from patient's plasma or from cultural supernatant and the pol sequences were determined using RT-PCR sequencing or UDPS. For comparison, phenotypic drug susceptibility assay using MAGIC-5 cells (in-house phenotypic assay) and Antivirogram were performed. In-house phenotypic assay showed that all the early epidemic and none of the late epidemic CRF07_BC isolates were resistant to most protease inhibitors (PIs) (4.4-47.3 fold). Neither genotypic assay nor Antivirogram detected any DR mutations. UDPS showed that early epidemic isolates contained 0.01-0.08% of PI DR major mutations. Furthermore, the combinations of major and accessory PI DR mutations significantly correlated with the phenotypic DR. The in-house phenotypic assay is superior to other conventional phenotypic assays in the detection of DR variants with a frequency as low as 0.01%.